Catalyst Dossier · compiled by CeliA 🧫
American Tungsten & Antimony Ltd (ATALF)
Biotechnology · market cap $47M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-01
Conference
Pipeline
1
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
American Tungsten & Antimony Ltd (ATALF) is a $47M market-cap company classified under biotechnology, developing Ferric Carboxymaltose (FCM) in a Phase 2 trial for Restless Legs Syndrome (RLS). The company name and sector classification are mismatched — the mining-oriented name contrasts with the biotech pipeline — and critical financial data including cash position, runway, and share count are not disclosed in available facts.
The catalyst path
- 2026-10-01Conferenceimp 2/10
- 2026-10-25Conferenceimp 2/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Ferric Carboxymaltose (FCM) | Phase 2 | Restless Legs Syndrome (RLS) |
Price & technical context
3-month
+0.0%
6-month
-50.0%
12-month
-42.9%
52-wk range
$0.02–$0.18
vs 50-day MA
-8.3%
vs 200-day MA
-40.7%
Realized vol
225.7%
Max drawdown
-88.9%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ATALF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.